Antibody specialist Leinco Technologies and precision medicine laboratory services provider CellCarta have announced a strategic collaboration aimed at developing proteomics solutions for immuno-oncology and other targeted therapeutics.
The new partnership will leverage Leinco's extensive antibody portfolio alongside CellCarta's catalogue of CPTAC antibodies developed for their Immuno-MRM assays.
The pair said in a statement that they hope the integration will provide researchers and clinicians with comprehensive tools for biomarker discovery and clinical research.
Comprehensive proteomics solutions for drug development
CellCarta's Immuno-MRM assays enable precise quantification of proteins in clinical samples, providing insights into protein expression and functionality.
These assays utilise antibodies validated to CPTAC consortium standards and support research from exploratory to clinical trials.
By combining Leinco's high-quality antibodies with CellCarta's Immuno-MRM resources, this new collaboration is aiming to improve the sensitivity and specificity of proteomic analyses, aiding the development of targeted therapies and personalised medicine.
"The combination of our rigorously validated antibodies — especially those proven for complex spatial analysis and IHC — with CellCarta's robust Immuno-MRM resources creates a truly powerful and scalable solution for our customers," said Patrick Leinert Jr, President of Commercial Operations at Leinco Technologies.
This strategic pairing is designed to provide confidence in data quality that is absolutely essential for accelerating drug development and biomarker discovery in all therapeutic areas.
Versatile offerings for research and clinical applications
The combined offerings of Leinco and CellCarta cater to a wide range of applications, from pilot-scale research to large-volume clinical use.
"By providing our immuno-MRM antibody library to Leinco, CellCarta hopes to make these validated antibodies more widely available to researchers using broad clinical research technologies," added Todd Chermak, Senior Vice President, Immunology & Proteomics Business Units at CellCarta.
Researchers will be able to use smaller catalogues for exploratory studies, while clinical labs can utilise large-volume reagents for routine testing.
This scalability will ensure that proteomics solutions meet the needs of both early-stage research and clinical diagnostics.
The pair say that their combined strengths will create a robust platform for drug development and biomarker discovery, with the collaboration enabling precise protein measurements, aiding the identification of novel biomarkers and evaluating therapeutic targets.